Cite
HARVARD Citation
Lampert, E. et al. (2020). Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses. Journal for immunotherapy of cancer. 8 (2), p. . [Online].